Nkarta shares early NKX019 trial results for myositis and systemic sclerosis

Nkarta Inc. presented initial data from its NKX019 cell therapy trial at the ACR Convergence 2026 meeting. Six myositis patients received a 4 billion‑cell dose and five showed moderate or major improvement, while seven systemic sclerosis patients were treated at the same dose and six achieved a response on the rCRISS‑25 scale. Across the 40 patients in the study, no serious safety events or deaths were reported. The company said it will test a higher 6 billion‑cell dose and will meet the FDA to discuss registration pathways.

The company indicated that further dosing and regulatory discussions are planned, which could shape the timing of a potential registrational trial and affect the stock’s valuation. Investors should note that the data are from very small cohorts and short follow‑up, so the clinical significance remains uncertain.

  • 1The trial included 40 patients across five autoimmune indications.
  • 2Five of six myositis participants (83%) treated with 4 billion NKX019 cells per dose achieved moderate or major responses.
  • 3Six of seven systemic sclerosis participants (86%) receiving the same dose achieved an rCRISS‑25 response or greater by Day 90.
  • 4The median reduction in modified Rodnan skin score for systemic sclerosis patients was 15 points at Day 90.
  • 5No cases of cytokine release syndrome, neurotoxicity, hemophagocytic syndrome, graft‑versus‑host disease, deaths, or treatment discontinuations were reported among the 40 patients.
  • 6Nkarta plans to evaluate a 6 billion‑cell dose and will engage the FDA on potential registration pathways, with additional data expected in the first half of 2027.

Sources